Search Results - "Pfreundschuh, M G"

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group by Pfreundschuh, M G, Rueffer, U, Lathan, B, Schmitz, N, Brosteanu, O, Hasenclever, D, Haas, R, Kirchner, H, Koch, P, Kuse, R

“…A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage…”
Get more information

Production of monoclonal antibodies against glucose oxidase, alkaline phosphatase and peroxidase. Their application in a highly sensitive antigen spot microassay by Steinmetz, H T, Pfreundschuh, M G

“…The production of monoclonal antibodies against peroxidase, alkaline phosphatase and glucose oxidase and the use of the respective enzyme monoclonal…”
Get more information

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group by Pfreundschuh, M G, Schoppe, W D, Fuchs, R, Pflüger, K H, Loeffler, M, Diehl, V

“…Thirty-two patients with advanced Hodgkin's lymphoma resistant to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin,…”
Get more information

Phase I study of intratumoral application of recombinant human tumor necrosis factor by Pfreundschuh, M G, Steinmetz, H T, Tüschen, R, Schenk, V, Diehl, V, Schaadt, M

Get more information

Peg-filgrastim (Peg-F) on day 4 of (R-)CHOP-14 chemotherapy compared to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of a randomized trial of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL) by Hartmann, F., Zeynalova, S., Nickenig, C., Reiser, M., Lengfelder, E., Duerk, H., de Witt, M., Schubert, J., Loeffler, M., Pfreundschuh, M. G.

“…Abstract only 19511 Background: Application of peg-f is recommended on day 2 of chemotherapy, but later application has not been studied. Objective: To compare…”
Get full text

Prognostic significance of maximal tumor size (MTS) in young patients with good-prognosis diffuse large B-cell lymphoma (DLBCL) treated with CHOP-like chemotherapy with and without rituximab: Analysis of the MabThera International Trial Group (MInT) study by Pfreundschuh, M. G., Hensel, M., Cavallin-Stahl, E., Vasova, I., Kvaloey, S., Gill, D., Walewski, J., Zinzani, P., Pettengell, R., Kuhnt, E.

“…Abstract only 8053 Purpose: To determine the impact of MTS in young (18 to 60 years) patients with DLBCL and aaIPI=0,1. Patients and Methods: Outcome of…”
Get full text

Dose-escalated CHOP plus etoposide (Hi-CHOEP) is not superior to base-line CHOEP in young good-prognosis patients with aggressive lymphoma: Results of a randomized DSHNHL trial by Pfreundschuh, M. G., Zeynalova, S., Duehrsen, U., Pflueger, K., Vrieling, T., Berdel, W. E., Mergenthaler, H., Einsele, H., Bentz, M., Schmitz, N., Loeffler, M.

“…Abstract only 7513 Background: The addition of etoposide to CHOP (CHOEP) resulted in improved outcome of young patients with good-prognosis aggressive lymphoma…”
Get full text

Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study by Pfreundschuh, M. G., Ho, A., Wolf, M., Cavallin-Stahl, E., Pettengell, R., Vasova, I., Belch, A., Walewski, J., Zinzani, P.-L., Mingrone, W., Loeffler, M.

“…Abstract only…”
Get full text

Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis by Pfreundschuh, M. G., Trümper, L., Ma, D., Österborg, A., Pettengell, R., Trneny, M., Shepherd, L., Waleswski, J., Zinzani, P.-L., Loeffler, M.

“…Abstract only…”
Get full text

Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis by Pfreundschuh, M. G., Trümper, L., Ma, D., Österborg, A., Pettengell, R., Trneny, M., Shepherd, L., Waleswski, J., Zinzani, P.-L., Loeffler, M.

“…Abstract only…”
Get full text

Comparison of multiple rosetting assays for detecting antibody reactivity of different immunoglobulin classes against surface antigens of benign and malignant tissue culture cells by Pfreundschuh, M G, Ueda, R, Rauterberg, E W, Dörken, B H, Shiku, H

“…Four serological assays for detection of antibody reactivity against surface antigens of benign and malignant cells have been evaluated. In all four assays,…”
Get more information

Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -: early stopping after the first interim analysis by Pfreundschuh, MG, Trumper, L, Ma, D, Osterborg, A, Pettengell, R, Trneny, M, Shepherd, L, Waleswski, J, Zinzani, PL, Loeffler, M

Get full text